Borghese Ottavia, Campion Margaux, Magana Marie, Pisani Angelo, Di Centa Isabelle
Department of Vascular Surgery, Foch Hospital, Suresnes, France; PhD school angio-cardio-thoracic pathophysiology and imaging, Sapienza University, Rome, Italy.
Department of Vascular Surgery, Foch Hospital, Suresnes, France.
J Med Vasc. 2024 Apr;49(2):65-71. doi: 10.1016/j.jdmv.2023.12.001. Epub 2024 Jan 18.
Despite the effort to increase the proportion of patients starting dialysis on native accesses, many of them are still dialyzed on tunnelled catheter. Catheter-related complications are often serious and responsible for re-hospital admission, high morbidity and mortality. Several multicenter trials have reported results in the use of tunnelled dialysis catheter (TDC). However, few single-center studies have been published to verify the outcome from real-world experience. This study presents our center's experience in managing such patients in the context of relevant literature.
Demographics and operative data were retrospectively collected from medical charts. A prospective follow-up was performed to investigate complications, number of re-hospitalizations and mortality. Kaplan-Meier estimate was used to evaluate catheter primary patency and patients' overall survival.
Among a total 298 haemodialysis accesses interventions, 105 patients (56 men, 53.3% and 49 women, 46.7%) with a median age of 65 years (range 32-88 years) were included in the study. All insertions were successful with an optimal blood flow achieved during the first session of dialysis in all cases. A catheter-related complication was detected in 33.3% (n=35) patients (48.6% infections; 28.6% TDC dysfunction; 14.3% local complications; 5.7% accidental catheter retractions; 2.8% catheter migrations). At a median follow-up of 10.5±8.5 months, a total of 85 patients (80.9%) was re-hospitalized, in 28 cases (26.7%) for a catheter-related cause. The median catheter patency rate was 122 days. At the last follow-up, 39 patients (37.1%) were still dialyzed on catheter, 30(28.6%) were dialyzed on an arteriovenous fistula and 7(6.7%) received a kidney transplantation. Two patients (2%) were transferred to peritoneal dialysis and two patients (2%) recover from renal insufficiency. Mortality rate was 23.8% (25 patients). Causes of death were myocardial infarction (n=13, 52%), sepsis (n=9, 36%); one patient (4%) died from pneumonia, one (4%) from uremic encephalopathy and one (4%) from massive hematemesis.
TDCs may represent the only possible access in some patients, however they are burned with a high rate of complications, re-hospital admission and mortality. Results from this institutional experience are in line with previously published literature data in terms of morbidity and mortality. The present results reiterate once more that TDC must be regarded as a temporary solution while permanent access creation should be prioritized. Strict surveillance should be held in patients having TDC for the early identification of complications allowing the prompt treatment and modifying the catheter insertion site whenever needed.
尽管一直在努力提高开始透析时使用自体血管通路的患者比例,但仍有许多患者通过隧道式导管进行透析。与导管相关的并发症通常很严重,是再次住院、高发病率和死亡率的原因。几项多中心试验报告了使用隧道式透析导管(TDC)的结果。然而,很少有单中心研究发表以验证实际临床经验的结果。本研究介绍了我们中心在相关文献背景下管理此类患者的经验。
从病历中回顾性收集人口统计学和手术数据。进行前瞻性随访以调查并发症、再次住院次数和死亡率。采用Kaplan-Meier估计法评估导管的初始通畅率和患者的总体生存率。
在总共298例血液透析血管通路干预中,纳入研究的有105例患者(56例男性,占53.3%;49例女性,占46.7%),中位年龄为65岁(范围32 - 88岁)。所有置管均成功,所有病例在首次透析时均实现了最佳血流量。33.3%(n = 35)的患者检测到与导管相关的并发症(48.6%为感染;28.6%为TDC功能障碍;14.3%为局部并发症;5.7%为导管意外回缩;2.8%为导管移位)。中位随访时间为10.5±8.5个月,共有85例患者(80.9%)再次住院,其中28例(26.7%)是由于与导管相关的原因。导管中位通畅率为122天。在最后一次随访时,39例患者(37.1%)仍通过导管进行透析,30例(28.6%)通过动静脉内瘘进行透析,7例(6.7%)接受了肾脏移植。2例患者(2%)转为腹膜透析,2例患者(2%)肾功能不全恢复。死亡率为23.8%(25例患者)。死亡原因是心肌梗死(n = 13,52%)、败血症(n = 9,36%);1例患者(4%)死于肺炎,1例(4%)死于尿毒症性脑病,1例(4%)死于大量呕血。
TDC可能是某些患者唯一可行的血管通路,然而其伴随着高并发症发生率、再次住院率和死亡率。本机构经验的结果在发病率和死亡率方面与先前发表的文献数据一致。目前的结果再次重申,TDC必须被视为一种临时解决方案,而应优先考虑建立永久性血管通路。对于使用TDC的患者应进行严格监测,以便早期识别并发症,从而能够及时治疗,并在需要时改变导管插入部位。